Market revenue in 2023 | USD 68.4 million |
Market revenue in 2030 | USD 370.6 million |
Growth rate | 27.3% (CAGR from 2023 to 2030) |
Largest segment | Pre-clinical |
Fastest growing segment | Pre-clinical |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pre-clinical, Clinical |
Key market players worldwide | Lonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy cdmo market will help companies and investors design strategic landscapes.
Pre-clinical was the largest segment with a revenue share of 66.08% in 2023. Horizon Databook has segmented the Spain cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
Some cell & gene therapy CDMO service providers in Spain are Catalent, Inc.; Boehringer Ingelheim; Lonza Group; Piramal Pharma Solutions; Jubilant; and AbbVie Contract Manufacturing. These companies are strengthening their market position by providing a wide range of services and developing novel pharmaceuticals.
Furthermore, the country has a rising number of ongoing clinical studies, which are expected to contribute to market growth. The growing number of innovations in clinical trials and the rising demand for generics & biologics are expected to drive market growth.
CDMOs in Spain invest in advanced technologies & infrastructure to enhance their capabilities in formulation development, process optimization, and manufacturing. The adoption of innovative technologies allows CDMOs to offer competitive services and support the development of novel pharmaceutical products.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain cell and gene therapy cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Spain cell and gene therapy cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account